Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N 6-methyladenosine of PARP1 mRNA and downregulating PTEN
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N 6-methyladenosine of PARP1 mRNA and downregulating PTEN ; volume:14 ; number:1 ; day:14 ; month:9 ; year:2021 ; pages:1 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (14.9.2021), 1, 12.2021
- Creator
-
Yang, Lei
Chen, Yi
Liu, Ning
Shi, QianCheng
Han, Xiaodong
Gan, Weidong
Li, Dongmei
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01153-8
- URN
-
urn:nbn:de:101:1-2021112521063940219950
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yang, Lei
- Chen, Yi
- Liu, Ning
- Shi, QianCheng
- Han, Xiaodong
- Gan, Weidong
- Li, Dongmei
- SpringerLink (Online service)
Other Objects (12)
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N 6-methyladenosine of PARP1 mRNA and downregulating PTEN
Therapeutic Targeting of MZF1‐AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression
Separation-of-function study of PARP1
The biological functions of PARP1
METTL3 and METTL14-mediated N6-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2
METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation
Effect and mechanism of downregulating the long-chain noncoding RNA TM4SF1-AS1 on the proliferation, apoptosis and invasion of gastric cancer cells
Long non-coding RNA LBX2-AS1 enhances glioma proliferation through downregulating microRNA-491-5p
Role of N6-methyladenosine in tumor neovascularization
Cellular characterization of PARP1 variants with altered enzymatic activities
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N 6-methyladenosine of PARP1 mRNA and downregulating PTEN
Therapeutic Targeting of MZF1‐AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression
Separation-of-function study of PARP1
The biological functions of PARP1
METTL3 and METTL14-mediated N6-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2
METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation
Effect and mechanism of downregulating the long-chain noncoding RNA TM4SF1-AS1 on the proliferation, apoptosis and invasion of gastric cancer cells
Long non-coding RNA LBX2-AS1 enhances glioma proliferation through downregulating microRNA-491-5p
Role of N6-methyladenosine in tumor neovascularization
Cellular characterization of PARP1 variants with altered enzymatic activities
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N 6-methyladenosine of PARP1 mRNA and downregulating PTEN
Therapeutic Targeting of MZF1‐AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression
Separation-of-function study of PARP1
The biological functions of PARP1
METTL3 and METTL14-mediated N6-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2
METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation
Effect and mechanism of downregulating the long-chain noncoding RNA TM4SF1-AS1 on the proliferation, apoptosis and invasion of gastric cancer cells
Long non-coding RNA LBX2-AS1 enhances glioma proliferation through downregulating microRNA-491-5p
Role of N6-methyladenosine in tumor neovascularization